Healthy
individuals have a normal variety of this gene, commonly known as A20. However,
individuals develop cancer if the gene cannot function properly. Thus, many
cancer patients are known to carry a dysfunctional variety of the gene.
individuals have a normal variety of this gene, commonly known as A20. However,
individuals develop cancer if the gene cannot function properly. Thus, many
cancer patients are known to carry a dysfunctional variety of the gene.
So, the
scientists created the first animal model of A20 to understand how this gene
works in the body. Based on results over the past decade, they expected that
these animals would develop cancer.
scientists created the first animal model of A20 to understand how this gene
works in the body. Based on results over the past decade, they expected that
these animals would develop cancer.
But to
their surprise, they found that the animals had a largely healthy life-span.
their surprise, they found that the animals had a largely healthy life-span.
The
work was carried out by Indian scientist Arnab De, during his doctorate study
at Columbia University with renowned Indian-American
immunologist Sankar Ghosh.
work was carried out by Indian scientist Arnab De, during his doctorate study
at Columbia University with renowned Indian-American
immunologist Sankar Ghosh.
The
work was recently published as a highlighted article in European Molecular
Biology Organization (EMBO) Reports, a peer-reviewed scientific journal that
covers research related to biology at a molecular level.
work was recently published as a highlighted article in European Molecular
Biology Organization (EMBO) Reports, a peer-reviewed scientific journal that
covers research related to biology at a molecular level.
Articles
chosen to be highlighted by EMBO are considered to be of "fundamental
relevance to a general readership".
chosen to be highlighted by EMBO are considered to be of "fundamental
relevance to a general readership".
"I
am hopeful that our work would contribute in a meaningful way towards testing
cancer drugs in animals" De, who is now a senior scientist at AbbVie Bioresearch
Center (formerly known as
Abbott Laboratories), told IANS over phone on Tuesday.
am hopeful that our work would contribute in a meaningful way towards testing
cancer drugs in animals" De, who is now a senior scientist at AbbVie Bioresearch
Center (formerly known as
Abbott Laboratories), told IANS over phone on Tuesday.
Henning
Walczak, scientific director of Cancer Research UK and chairman of Cancer Biology
at University College London, reacting to this publication, said in an e-mail:
"In healthy individuals, A20, also known as TNFAIP3, works beneficially to
clear invading microbes. However, if A20 cannot function as a result of
hereditary mutations or infection, it results in serious pathologies, including
cancer."
Walczak, scientific director of Cancer Research UK and chairman of Cancer Biology
at University College London, reacting to this publication, said in an e-mail:
"In healthy individuals, A20, also known as TNFAIP3, works beneficially to
clear invading microbes. However, if A20 cannot function as a result of
hereditary mutations or infection, it results in serious pathologies, including
cancer."
"Before
this work, there was no animal model to understand how this critical tumour
suppressor works. Having an animal model now, significantly improves our
ability to investigate how A20 works, and this study already goes a long way in
clarifying how A20 fails to work properly in patients and, as a consequence
thereof, in developing potential cancer therapeutics", he concludes.
this work, there was no animal model to understand how this critical tumour
suppressor works. Having an animal model now, significantly improves our
ability to investigate how A20 works, and this study already goes a long way in
clarifying how A20 fails to work properly in patients and, as a consequence
thereof, in developing potential cancer therapeutics", he concludes.
Chozha
Rathinam and Teruki Dainichi, currently at Kyoto
University (Japan), are the other authors in
this publication.
Rathinam and Teruki Dainichi, currently at Kyoto
University (Japan), are the other authors in
this publication.
Cancers
figure among the leading causes of morbidity and mortality worldwide, with
approximately 14 million new cases and 8.2 million cancer related deaths in
2012, according to the World Health Organisation (WHO). The number of new cases
is expected to rise by about 70 per cent over the next 2 decades, according to
WHO.
figure among the leading causes of morbidity and mortality worldwide, with
approximately 14 million new cases and 8.2 million cancer related deaths in
2012, according to the World Health Organisation (WHO). The number of new cases
is expected to rise by about 70 per cent over the next 2 decades, according to
WHO.
Bottom
of Form
of Form
No comments:
Post a Comment